Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation.
Kolik. L G LG; Nadorova. A V AV; Kozlovskaya. M M MM
Key Findings
- Selank (0.3 mg/kg, i.p.) eliminated anxiety in rats undergoing 48‑hour alcohol withdrawal
- Selank prevented the development of mechanical allodynia (pain sensitivity) during withdrawal
- Selank did not affect the amount of ethanol the rats consumed
Practical Outcomes
- For biohackers interested in managing alcohol withdrawal, selank looks promising as an anxiolytic that might also reduce withdrawal‑related pain. However, because the evidence is limited to rats, any human use would be experimental, and appropriate dosing, safety, and legal status are still unknown. Further clinical research is needed before it can be recommended as a protocol.
Summary
In a rat study, a single injection of the peptide selank (0.3 mg/kg) stopped the anxiety and pain‑like symptoms that usually appear when the animals stopped drinking alcohol, without changing how much they drank. This points to selank’s potential to ease alcohol‑withdrawal discomfort, but it’s only been shown in animals so far.
Abstract
We studied the effects of selank on the development of symptoms of acute 48-h alcohol withdrawal in outbred rats drinking 10 % ethanol as the only source of fluid for 24 weeks. In alcohol-preferring animals (mean daily ethanol intake >5.0 g/kg) allowed free choice between 10 % ethanol and water, single intraperitoneal injection of selank in a dose of 0.3 mg/kg eliminated anxiety induced by ethanol withdrawal in tests elevated plus maze and social interaction tests and prevented the formation of mechanical allodynia without affecting ethanol consumption. The fi ndings suggest that selank is effective in eliminating of alcohol withdrawal symptoms in rats.
Study Information
pubmed
2014
2014-06-10T00:00:00.000Z
10.1007/s10517-014-2490-4